Neuronal growth-inhibitory factor (metallothionein-3): Structure-function relationships

FEBS Journal

Volumn 277, Issue 14, 2010, Pages 2912-2920

  Ding, Zhi Chun ^a   Ni, Feng Yun ^a   Huang, Zhong Xian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

metallothionein (MT); mutation; neuronal growth inhibitory factor (GIF); structure function relationship

Indexed keywords

GROWTH INHIBITOR; METAL; METALLOTHIONEIN III; THIOL;

GROWTH INHIBITION; HOMEOSTASIS; HUMAN; MOLECULAR DYNAMICS; NERVE FIBER GROWTH; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; PROTEIN ENGINEERING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954355688     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07716.x     Document Type: Short Survey

References (28)

1. Margoshes M Vallee BL (1957) A cadmium protein from equine kidney cortex. J Am Chem Soc 79, 4813 4814.
2. Binz PA Kagi JHR (1999) Metallothionein IV, Metallothionein: Molecular Evolution and Classification. Birkhause
3. Palmiter RD (1987) Molecular biology of metallothionein gene expression. Experientia Suppl 52, 63 80.
4. Uchida Y Tomonaga M (1989) Neurotrophic action of Alzheimer's disease brain extract is due to the loss of inhibitory factors for survival and neurite formation of cerebral cortical neurons. Brain Res 481, 190 193.
5. Uchida Y Ihara Y (1995) The N-terminal portion of growth inhibitory factor is sufficient for biological activity. J Biol Chem 270, 3365 3369.
6. Sewell AK, Jensen LT, Erickson JC, Palmiter RD Winge DR (1995) Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. Biochemistry 34, 4740 4747.
7. Robbins AH, McRee DE, Williamson M, Collett SA, Xuong NH, Furey WF, Wang BC Stout CD (1991) Refined crystal structure of Cd, Zn metallothionein at 2.0 A resolution. J Mol Biol 221, 1269 1293.
8. Braun W, Vasak M, Robbins AH, Stout CD, Wagner G, Kagi JH Wuthrich K (1992) Comparison of the NMR solution structure and the x-ray crystal structure of rat metallothionein-2. Proc Natl Acad Sci USA 89, 10124 10128.
9. Wang H, Zhang Q, Cai B, Li H, Sze KH, Huang ZX, Wu HM Sun H (2006) Solution structure and dynamics of human metallothionein-3 (MT-3). FEBS Lett 580, 795 800. (Pubitemid 43152298)
10. Oz G, Zangger K Armitage IM (2001) Three-dimensional structure and dynamics of a brain specific growth inhibitory factor: metallothionein-3 Biochemistry 40, 11433 11441.
11. Zheng Q, Yang WM, Yu WH, Cai B, Teng XC, Xie Y, Sun HZ, Zhang MJ Huang ZX (2003) The effect of the EAAEAE insert on the property of human metallothionein-3. Protein Eng 16, 865 870.
12. Ni FY, Cai B, Ding ZC, Zheng F, Zhang MJ, Wu HM, Sun HZ Huang ZX (2007) Structural prediction of the beta-domain of metallothionein-3 by molecular dynamics simulation. Proteins 68, 255 266.
13. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW Schreiber SL (1994) Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76, 933 945.
14. Williamson MP (1994) The structure and function of proline-rich regions in proteins. Biochem J 297 (Pt 2 249 260.
15. Cai B, Zheng Q, Teng XC, Chen D, Wang Y, Wang KQ, Zhou GM, Xie Y, Zhang MJ, Sun HZ et al. (2006) The role of Thr5 in human neuron growth inhibitory factor. J Biol Inorg Chem 11, 476 482.
16. Cai B, Ding ZC, Zhang Q, Ni FY, Wang H, Zheng Q, Wang Y, Zhou GM, Wang KQ, Sun HZ et al. (2009) The structural and biological significance of the EAAEAE insert in the alpha-domain of human neuronal growth inhibitory factor. FEBS J 276, 3547 3558.
17. Hasler DW, Jensen LT, Zerbe O, Winge DR Vasak M (2000) Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. Biochemistry 39, 14567 14575.
18. Romero-Isart N, Jensen LT, Zerbe O, Winge DR Vasak M (2002) Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1. J Biol Chem 277, 37023 37028.
19. Chung RS, Holloway AF, Eckhardt BL, Harris JA, Vickers JC, Chuah MI West AK (2002) Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III. Biochem J 365, 323 328.
20. Faller P, Hasler DW, Zerbe O, Klauser S, Winge DR Vasak M (1999) Evidence for a dynamic structure of human neuronal growth inhibitory factor and for major rearrangements of its metal-thiolate clusters. Biochemistry 38, 10158 10167.
21. Faller P Vasak M (1997) Distinct metal-thiolate clusters in the N-terminal domain of neuronal growth inhibitory factor. Biochemistry 36, 13341 13348.
22. Jiang LJ, Vasak M, Vallee BL Maret W (2000) Zinc transfer potentials of the alpha - and beta-clusters of metallothionein are affected by domain interactions in the whole molecule. Proc Natl Acad Sci USA 97, 2503 2508.
23. Ding ZC, Zheng Q, Cai B, Yu WH, Teng XC, Wang Y, Zhou GM, Wu HM, Sun HZ, Zhang MJ et al. (2007) Effect of alpha-domain substitution on the structure, property and function of human neuronal growth inhibitory factor. J Biol Inorg Chem 12, 1173 1179.
24. Ding ZC, Teng XC, Zheng Q, Ni FY, Cai B, Wang Y, Zhou GM, Sun HZ, Tan XS Huang ZX (2009) Important roles of the conserved linker-KKS in human neuronal growth inhibitory factor. Biometals 22, 817 826.
25. 2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. Biochem J 344 (Pt 1 253 258.
26. Chen Y, Irie Y, Keung WM Maret W (2002) S-nitrosothiols react preferentially with zinc thiolate clusters of metallothionein III through transnitrosation. Biochemistry 41, 8360 8367.
27. Ding ZC, Teng XC, Cai B, Wang H, Zheng Q, Wang Y, Zhou GM, Zhang MJ, Wu HM, Sun HZ et al. (2006) Mutation at Glu23 eliminates the neuron growth inhibitory activity of human metallothionein-3. Biochem Biophys Res Commun 349, 674 682.
28. 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372, 216 223.